Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.

Leuk Lymphoma

Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada.

Published: September 2021

Download full-text PDF	Source
http://dx.doi.org/10.1080/10428194.2021.1901097	DOI Listing

Publication Analysis

nelarabine-containing regimen

regimen daratumumab

daratumumab effective

effective salvage

salvage therapy

therapy bridge

bridge allogeneic

allogeneic hematopoietic

hematopoietic stem

stem cell

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!